娄底找算命好的大师(三亚算命大师哪个准) (今日更新中)

SAN DIEGO (KGTV) -- Caltrans is alerting San Diegans of a closure that will shut down SR-163 Wednesday and Thursday nights.According to the agency, all lanes of SR-163 will close between Interstate 8 and Genesee Avenue between 11 p.m. and 5 a.m. Wednesday and Thursday nights.Caltrans says the northbound lanes will close Wednesday night and the southbound lanes will shut down Thursday night. At no time will the road close in both directions at the same time.RELATED: Check traffic conditionsSome of the lanes will begin closing at 7 p.m. with all the lanes closing by 11 p.m. The closure will also include the eastbound and westbound I-8 connector ramps to northbound SR-163. The eastbound Friars Road on-ramp to northbound SR-163 will also be closed.Caltrans says all southbound motorists will be rerouted to southbound I-805. Northbound travelers will be rerouted to eastbound I-8.The closures will take place so crews can continue installing falsework on the Friars Road Bridge. 1002

SAN DIEGO (KGTV) - Border officials say the man shot and killed on Friday night by a Border Patrol agent behind the Las Americas Premium Outlets mall was trying to enter the U.S. illegally.A statement from Aaron Heitke, Chief Patrol Agent for the U.S. Border Patrol, San Diego Sector reads:“On Friday, October 23, 2020, at approximately 5:45 p.m., a United States Border Patrol agent responded to apprehend a man illegally entering the United States immediately west of the port of entry in San Ysidro, California. During the arrest, an altercation ensued and the agent discharged his firearm, wounding the man, who was later identified as an adult Mexican national. Nearby agents and law enforcement personnel responded immediately and initiated lifesaving efforts until emergency medical services arrived. At approximately 6:25 p.m. the man was pronounced deceased at the scene. The investigation is currently being led by the San Diego Police Department. Customs and Border Protection will continue to fully cooperate with the ongoing investigation. The specifics of this incident have also been shared with FBI, DHS OIG and CBP Office of Professional Responsibility. Additional updates will be provided by the San Diego Police Department, inquiries should be directed to them.”SDPD added Saturday that the 30-year-old man was shot once in the torso by the agent after he fought the agent, who sustained minor injuries.Social justice leaders with the American Friends Service Committee and Alliance San Diego have sent a letter to SDPD calling in part for an independent investigation to be handled only by police, not border officials or unions. Part of the letter reads, “Any involvement or coordination with these agencies, and specifically with CIIT has the potential to corrupt the investigation and could be considered an obstruction of justice.”Pedro Rios with the American Friends Service Committee said that he and others are considering holding a demonstration on Sunday. “I think for us it's important to ensure that people are treated with dignity regardless of who they are and we shouldn't jump to conclusions about the person who is now a victim and is now deceased,” Rios told ABC 10News on Saturday. He added, “I think we should permit the investigation — an unobstructed investigation — to move forward and that way we get to know exactly what took place that led to the demise of this individual.”There's now a call for evidence related to the shooting to be released right away. “We know that there's a lot of surveillance cameras in the area, not only belonging to Customs and Border Protection and [the] Department of Homeland Security but also the Las Americas mall has a lot of cameras in the area,” said Rios.Officials are not releasing the name of the man who was shot or the name of the agent who fired at him. 2848

SAN DIEGO (KGTV) — County health officials say with the summer months well underway, they've seen an uptick in the number of children that have needed to be rescued from private pools after nearly drowning.Officials say there have been 49 rescues in private pools, beaches, and bays from March through July, compared to 37 in the same period in 2019 and 33 in 2018. Nearly all of those rescued this year have needed to be taken to the hospital for treatment.Of those 49 that occurred this year, 28 were in pools and 14 were in the ocean, lakes, or bays. The rest did not report a specific body of water. Many public pools have been closed since March due to the pandemic."Parents and guardians must take the necessary precautions to keep these incidents from happening," said Wilma Wooten, county public health officer, said. "Children who swim in pools at home are at higher risk of drowning, especially as parents struggle to supervise their children while continuing to work at home through the summer months because of the novel coronavirus."The county says it's important to teach children to swim, never leave a child unsupervised in or near water, avoid alcohol if you're swimming, and learn CPR.At home, the county recommends installing a fence around the pool and hot tub, installing pool alarms, and keeping an eye on drains and pool toys that could be a tripping hazard. 1389

SAN DIEGO (KGTV) -- As an active 45-year-old man who loves to surf and take adventures with his daughter, Bryce Olson was the last person his friends expected to get cancer.In 2014, a call while at work confirmed it: stage IV metastatic prostate cancer.Metastatic means the cancer has spread to other parts of the body, lymph nodes, bones or other organs.“It was just shocking and sad and I didn’t know anything about this stuff, so I just...I rolled into whatever my doctors were recommending," said Olson.He says the standard of care - surgery, chemotherapy, and the initial hormone therapy - wasn't working.“I started coming to terms with my own mortality. I didn’t even think I’d see my kid get out of elementary school and I was losing hope," said Olson.Olson says he wanted to make his final days count. The Intel employee started learning about precision medicine and eventually pursued DNA sequencing to find out exactly what was driving his disease.“I'm a believer in profiling your tumor at a molecular level and trying to understand what’s driving your unique disease, and then taking that data and then finding the right drug for the right person at the right time," said Olson.His results led him to a clinical trial in Los Angeles, where he was a perfect molecular match for the drug being tested.Four years later, Olson's precision medicine journey led him to San Diego's Epic Sciences.“We're actually going to a place where no test has gone before," said Murali Prahalad, President and CEO of Epic Sciences. "These are metastatic patients; the disease has already spread. And we’re trying to understand in the later stages of the disease when it’s far more complicated, how do you then understand which treatment is the right one.”Patients like Olson have two treatment options, chemotherapy or hormone therapy."It's very important to know which medicine is going to work," said Pascal Bamford, Chief Scientific Officer of Epic Sciences, "At the metastatic end of this disease every week, every day, every month is critically important."The company has created a blood test to make the choice easier, called the Oncotype DX AR-V7 Nucleus Detect.If the antigen AR-V7 is detected in a patient, they have built a resistance to hormone therapy, meaning chemotherapy would likely be a better treatment option.“We think it’s very groundbreaking, to say this is the first test that can tell a patient which drug to go on to extend their life," said Ryan Dittamore, Chief of Medical Innovation.Dittamore says the test helps provides certainty for doctors. Patients they've studied have almost doubled their life expectancy with the AR-V7 test.“It can mean the world, not only to patients but loved ones," said Dittamore.Olson was AR-V7 negative, meaning he could continue hormone therapy.Four months in, it's working. “I’m going to see my kid not only get out of high school but college and get married. I’m fully confident that I can do that because I’m just going to keep pushing," said Olson.In December 2018 the AR-V7 test will be covered by Medicare, meaning thousands of more men will have access to it. 3150

SAN DIEGO (KGTV) - Anyone touched by Alzheimer's knows how painful the disease is. "It's affected my family. It's affected most families. It's such a prevalent disease. As people get older, it becomes quite likely this will become an issue," said Paul Aisen, director of USC's Alzheimer's Therapeutic Research Clinic (ACTC).Aisen's team began their research in San Diego many years ago and teamed up with USC about four years ago. He's spent over 30 years trying to solve Alzheimer's mysteries and is leading the upcoming clinical trial.Aisen says the large-scale study is the culmination of decades of work from scientists worldwide."Our focus lately has been trying to alter the disease, prevent it, or significantly slow its progression. How should we do that? We think attacking amyloid early is the most promising approach," said Aisen. Researchers believe sticky amyloid deposits, which form on the brain later in life, start the Alzheimer's process. Aging, genetics, and lifestyle factors can all contribute to amyloid build-up.The worldwide clinical trial aims to target amyloid. A drug called BAN2401 will be delivered intravenously, designed to bind to the sticky amyloid. The binding neutralizes beta amyloid and helps "tag" it, so the immune system can recognize it and clear it from the brain. A previous phase 2 study showed that BAN2401 removes brain amyloid and possibly slows cognitive decline.They're seeking participants over 50 who are not yet showing symptoms of Alzheimer's but do have elevated amounts of amyloid on their brain. Researchers can determine that through a PET scan or spinal tap. "We think that the most promising approach of all is to take a vigorous attack on amyloid while the brain is still functioning normally. And we can see amyloid in people many years before they develop the symptoms of Alzheimer's."Investigators hope that by treating a patient with BAN2401 very early in the disease, before symptoms occur, it will significantly slow disease progression. "If we're successful, it will have a huge impact on human health," said Aisen. There will be 100 sites worldwide for the study, including major cities like San Diego and Los Angeles. Study participants will receive treatment for four years, given either the drug or a placebo. Results are expected in seven years, Aisen says. If you or a loved one wants to participate, learn more here.Screening will officially begin in May. 2438

来源：资阳报